These anti-TNF-α monoclonal antibodies have been demonstrated to be effective in RA [116], juvenile idiopathic arthritis [117], psoriatic arthritis [118], ankylosing spondylitis [119], and inflammatory bowel disease [120], and each has been clinically applied. This evidence concerns the gene TNF and rheumatoid arthritis.